

5.85.047

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2023
<b>Subsection:</b>	Hematological Agents	<b>Original Policy Date:</b>	January 13, 2023
<b>Subject:</b>	Rolvedon	<b>Page:</b>	1 of 3

---

**Last Review Date:** June 15, 2023

## Rolvedon

### Description

#### Rolvedon (eflapegrastim-xnst)

#### Background

Rolvedon (eflapegrastim-xnst) is a recombinant human granulocyte growth factor that binds to granulocyte colony-stimulating factor (G-CSF) receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration, and survival (1).

#### Regulatory Status

FDA-approved indication: Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia (1).

Limitations of Use: Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation (1).

Rolvedon contains warnings for the following: splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell crisis in patients with sickle cell disorders, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, potential for tumor growth stimulatory effects on malignant cells, myelodysplastic syndrome (MDS) and acute

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2023
<b>Subsection:</b>	Hematological Agents	<b>Original Policy Date:</b>	January 13, 2023
<b>Subject:</b>	Rolvedon	<b>Page:</b>	2 of 3

---

myeloid leukemia (AML) in patients with breast and lung cancer, aortitis, and nuclear imaging (1).

The safety and effectiveness of Rolvedon in pediatric patients less than 18 years of age have not been established (1).

### Related policies

Leukine, Neulasta, Neupogen

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Rolvedon may be considered **medically necessary** if the conditions indicated below are met.

Rolvedon may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Prophylaxis for chemotherapy induced febrile neutropenia
2. Treatment of chemotherapy induced febrile neutropenia

**AND** the following for **ALL** diagnoses:

- a. **NOT** used in combination with another granulocyte colony-stimulating factor (G-CSF)

## Prior – Approval *Renewal* Requirements

Same as above

### Policy Guidelines

## Pre - PA Allowance

None

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2023
<b>Subsection:</b>	Hematological Agents	<b>Original Policy Date:</b>	January 13, 2023
<b>Subject:</b>	Rolvedon	<b>Page:</b>	3 of 3

---

## Prior - Approval Limits

**Duration**      6 months

## Prior – Approval *Renewal* Limits

Same as above

### Rationale

#### Summary

Rolvedon is a recombinant human granulocyte growth factor that binds to granulocyte colony-stimulating factor (G-CSF) receptors and is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. The safety and effectiveness of Rolvedon in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Rolvedon while maintaining optimal therapeutic outcomes.

#### References

1. Rolvedon [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; September 2022.
2. NCCN Clinical Practice Guidelines in Oncology® Hematopoietic Growth Factors 2023. National Comprehensive Cancer Network, Inc. Accessed on April 13, 2023.

### Policy History

Date	Reason
October 2022	Addition to PA
March 2023	Annual review and reference update
June 2023	Annual review and reference update

### Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 15, 2023 and is effective on July 1, 2023.**